Department of Science, School of Engineering, Amrita Vishwa Vidyapeetham, Coimbatore, 641112, India.
Department of Chemistry, Sookmyung Women's University, Seoul 04310, Korea.
Chem Commun (Camb). 2021 Sep 21;57(75):9614-9617. doi: 10.1039/d1cc00118c.
The endogenous HS-driven theranostic H2S-Gem has been invented. The theranostic prodrug H2S-Gem is selectively activated in cancer cells, releasing active gemcitabine with a simultaneous fluorescence turn-on. H2S-Gem selectively inhibited cancer cell growth compared to the mother chemotherapeutic gemcitabine. Overall, it is a unique protocol for tracking and transporting chemotherapeutic agents to tumor areas without the guidance of tumor-directive ligands.
内源性 HS 驱动的治疗性 H2S-Gem 已被发明。治疗性前药 H2S-Gem 可在癌细胞中选择性激活，同时释放具有荧光开启的活性吉西他滨。与母体化疗药物吉西他滨相比，H2S-Gem 选择性抑制癌细胞生长。总体而言，这是一种独特的方案，可在没有肿瘤导向配体指导的情况下跟踪和输送化疗药物到肿瘤区域。
